Autopsy report · NCT00617929

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

“Replaced by another protocol”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 years 9 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Cancer

Interventions

anti-thymocyte globulin; rituximab; clofarabine; stem cell transplantation

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
  “To be replaced by a different protocol” (96% match in meaning)
• Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
  “to be replaced with a different protocol” (96% match in meaning)
• RCT for Women With a Persisting Pregnancy of Unknown Location
  “A new protocol was written to replace this protocol.” (85% match in meaning)
• Bacteriophage Therapy in Patients With Prosthetic Joint Infections
  “Changes to protocol design” (82% match in meaning)
• Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury
  “revised and combined with another protocol” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.